Evidence map›Paper›PMID 33801057›Full record

ReviewMolecules (Basel, Switzerland)2021

Cannabinoid Quinones-A Review and Novel Observations.

Natalya M Kogan, Maximilian Peters, Raphael Mechoulam

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Quinones as Neuroprotective Agents.Antioxidants (Basel, Switzerland) · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Natural vs. artificial cannabinoid oils: the comparison of their antioxidant activities.European food research and technology = Zeitschrift fur Lebensmittel-Untersuchung und -Forschung. A · 2023
    Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Natalya M KoganInstitute for Drug Research, Medical Faculty, Hebrew University, Jerusalem 91120, Israel.ORCID 0000-0002-6792-3841
Maximilian PetersInstitute for Drug Research, Medical Faculty, Hebrew University, Jerusalem 91120, Israel.ORCID 0000-0001-6100-3270
Raphael MechoulamInstitute for Drug Research, Medical Faculty, Hebrew University, Jerusalem 91120, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A cannabinoid anticancer para-quinone, HU-331, which was synthesized by our group five decades ago, was shown to have very high efficacy against human cancer cell lines in-vitro and against in-vivo grafts of human tumors in nude mice. The main mechanism was topoisomerase IIα catalytic inhibition. Later, several groups synthesized related compounds. In the present presentation, we review the publications on compounds synthesized on the basis of HU-331, summarize their published activities and mechanisms of action and report the synthesis and action of novel quinones, thus expanding the structure-activity relationship in these series.

Indexed as

Neoplasms, ExperimentalQuinonesTopoisomerase II InhibitorsAnimalsCannabidiolDNA Topoisomerases, Type IIHumansMiceMice, NudeNeoplasm ProteinsPoly-ADP-Ribose Binding ProteinsCannabidiolcannabidiol hydroxyquinoneDNA Topoisomerases, Type IINeoplasm ProteinsPoly-ADP-Ribose Binding ProteinsQuinonesTOP2A protein, humanTopoisomerase II Inhibitorsanti-cancercannabinoidquinonesstructure-activity relationship

Identifiers

PMID33801057
PMCPMC8003933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.